Telix ADRs rise after FDA approves Pixclara brain imaging
Telix Pharmaceuticals Limited ADRs gained after the FDA approved its new drug application for Pixclara, used in brain cancer imaging; ADRs rose 7.9% to $12.18 in premarket.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
6 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
FDA approves Telix brain cancer imaging drug Pixclara
Telix said the FDA approved its brain cancer imaging drug Pixclara, with the stock up in premarket trading.
FDA approves Telix brain cancer imaging drug Pixclara
FDA approves Telix brain cancer imaging drug Pixclara
The Food and Drug Administration approved Telix Pharmaceuticals’ NASDAQ:TLX Pixclara, a radioactive imaging drug used to help evaluate patients with glioma, the company said Sunday.Pixclara, also known as floretyrosine F 18, is approved for use with positron emission tomography to help distinguish…
FDA Approves Telix's Brain Cancer Imaging Drug Pixclara
MELBOURNE, Australia and INDIANAPOLIS, Sept. 14, 2026 // -- Telix Pharmaceuticals Limited (ASX:TLX, NASDAQ:TLX, "Telix") today announces that the United States (U.S.) Food and Drug Administration (FDA) has approved its New Drug Application (NDA) for Pixclara® (floretyrosine F 18 or 18F-FE…
Telix Pharmaceuticals Says FDA Approves Telix Brain Cancer Imaging Drug Pixclara
Telix Pharmaceuticals Limited ASX:TLX